CONTINUING TO SUPPORT THE NATION’S EMERGING SECTORS As an innovative financier and development facilitator of the ICT sector, MDV is now extending its portfolio into the rapidly emerging biotechnology sector. MDV has established its own independent team of credit and research professionals and a dedicated fund towards advancing this vibrant sector as one of the main engines of growth for the nation’s economy. Your independent vision and leadership with full control. Building a company takes enormous effort and determination from the start. It will ultimately be your vision and leadership that will lead your company to success. MDV takes no stake in your company. Instead we offer the following advantages compared to venture capitalists and other financiers: * Clear and transparent exit mechanism ie repayment of financing * Flexible repayment periods * Independent of stock market conditions * Independent of your company valuation * Maximising returns to shareholders, including existing Venture Capital investors Your application process is accelerated due to our highly-efficient procedures. Upon securing your Biotech project, you would want someone to act on it fast. With complete documentation, we will process your application within a short timeframe. Biotech projects are very time-sensitive and work best when implemented within a specific window of opportunity. Due to our in-depth knowledge of the industry and highly-effective procedures, MDV works fast so that you can

Share and Enjoy:
  • Digg
  • del.icio.us
  • Facebook
  • NewsVine
  • Reddit
  • StumbleUpon
  • Google Bookmarks
  • Yahoo! Buzz
  • Twitter
  • Technorati
  • Live
  • LinkedIn
  • MySpace
  • StumbleUpon
  • Technorati
  • Tipd


swine flu April 30 bio tech companies stand to make hundreds of millions from vaccine,resit taking any vaccine .wash your hands stock up on food now avoid public places. here are NOVOVAX finacial estamets realesed march notice the excception to there prediction and how it is phrased did they now this was coming? NOVAVAX INC. (NVAX.O) Latest Forecast* No. of Yr ago analysts qtr EPS (basic, $/shr) -0.10 — – 0.13 Net ($ million) -6.1 — – 6.2 Total revenue ($ million) 1.3 1.1 3 2.2 *Source: Reuters Estimates #Excludes extraordinary, special or one-time items –Novavx said the prior year quarter included a gain in the sale of product assets as well as a $1 million license renewal fee received in December 2005. –For the latest fourth quarter, three analysts on average expected the biopharmaceutical company to post a loss of 9 cents a share, items but including stock-based compensation, according to Reuters Estimates. (Reporting by Esha Dey in Bangalore)

Share and Enjoy:
  • Digg
  • del.icio.us
  • Facebook
  • NewsVine
  • Reddit
  • StumbleUpon
  • Google Bookmarks
  • Yahoo! Buzz
  • Twitter
  • Technorati
  • Live
  • LinkedIn
  • MySpace
  • StumbleUpon
  • Technorati
  • Tipd


In an interview with CNBC-TV18, MD Kanther, Chairman, Mavens Biotech, spoke about the latest happenings in his company and sector.

Share and Enjoy:
  • Digg
  • del.icio.us
  • Facebook
  • NewsVine
  • Reddit
  • StumbleUpon
  • Google Bookmarks
  • Yahoo! Buzz
  • Twitter
  • Technorati
  • Live
  • LinkedIn
  • MySpace
  • StumbleUpon
  • Technorati
  • Tipd